USPTO Issued Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880
REDWOOD CITY, CA, USA I May 26, 2016 I Coherus BioSciences, Inc. (CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that the United States Patent and Trademark Office (USPTO) issued to Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880. These patents generally concern formulations of adalimumab, the active biological ingredient in Coherus’ Humira biosimilar, CHS-1420, currently in Phase 3. The formulations described in these patents achieve stability without need for polyols or surfactants.
“We welcome these USPTO decisions,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “The issuance of these U.S. patents, along with pending foreign counterparts, as well as the USPTO’s recent decision instituting our IPR against AbbVie’s U.S. Patent 8,889,135 validates our differentiated intellectual property strategy. We view these achievements as further confirmation of Coherus’ leadership in biosimilar intellectual property and the effectiveness of our platform. We continue to execute our plan for the development and commercialization of our Humira biosimilar, CHS-1420, consistent with our corporate strategy. These developments, along with this continued execution, reinforce our previous guidance anticipating BLA filing following successful Phase 3 completion.”
About Coherus BioSciences, Inc.
Coherus is a leading pure-play global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit www.coherus.com.
SOURCE: Coherus BioSciences
Post Views: 10
USPTO Issued Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880
REDWOOD CITY, CA, USA I May 26, 2016 I Coherus BioSciences, Inc. (CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that the United States Patent and Trademark Office (USPTO) issued to Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880. These patents generally concern formulations of adalimumab, the active biological ingredient in Coherus’ Humira biosimilar, CHS-1420, currently in Phase 3. The formulations described in these patents achieve stability without need for polyols or surfactants.
“We welcome these USPTO decisions,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “The issuance of these U.S. patents, along with pending foreign counterparts, as well as the USPTO’s recent decision instituting our IPR against AbbVie’s U.S. Patent 8,889,135 validates our differentiated intellectual property strategy. We view these achievements as further confirmation of Coherus’ leadership in biosimilar intellectual property and the effectiveness of our platform. We continue to execute our plan for the development and commercialization of our Humira biosimilar, CHS-1420, consistent with our corporate strategy. These developments, along with this continued execution, reinforce our previous guidance anticipating BLA filing following successful Phase 3 completion.”
About Coherus BioSciences, Inc.
Coherus is a leading pure-play global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit www.coherus.com.
SOURCE: Coherus BioSciences
Post Views: 10
